'We've reached an important milestone in the evolution of the BOL-148 program,' said Carey Turnbull, Founder and CEO of Ceruvia Lifesciences. 'Over the past two years we've refined both the science and the development strategy behind this program. By committing the capital required to complete this integrated Phase 1/2 study, we're now in a position to evaluate both the safety and therapeutic potential of BOL-148 within a single clinical study.'.
“我们在BOL-148项目的演进过程中达到了一个重要的里程碑，”Ceruvia Lifesciences的创始人兼首席执行官Carey Turnbull表示。“在过去两年中，我们完善了该项目背后的科学基础和发展策略。通过投入完成这项整合性1/2期临床试验所需的资金，我们现在能够在单一的临床研究中评估BOL-148的安全性和治疗潜力。”